XTL Biopharmaceuticals Ltd. announced consolidated earnings results for the first quarter ended March 31, 2016. The company reported an operating loss for the quarter ended March 31, 2016 of $602,000 compared with $376,000 for the same period in 2015 reflecting increased spending on research and development. The Company reported a total net loss for the period ended March 31, 2016 of approximately $600,000 or $0.002 per share, compared to $1.1 million or $0.005 per share in the same period in 2015. Total net loss in the first quarter of 2015 included a loss from discontinued operations of approximately $689,000. Total loss from continuing operations was $577,000 against $387,000 a year ago. Total loss for the period attributable to equity holders of the company was $577,000 against $1,078,000 a year ago. Basic and diluted loss per share from continuing continuing operations was $0.002 against $0.003 a year ago.